Award Winning Team with Large Network and Experience of 300+ Projects
Who We Are
NOVEL is an Award Winning Team of Experienced Professionals with Expertise in Health Economics and Outcomes Research, Market Access, Pricing, Payer Strategy, Publications, GVD and Reimbursement.
Our Team is Comprised of Strategists, ex-Payers, HEOR Experts and Market Access Professionals.
NOVEL's Team has Published More than 160+ Peer-Reviewed Publications in Top Journals and Conferences.
Our Team has Experience Leading Projects for Majority of Top 50 Pharmaceutical and Medical Device Companies. Novel Health has led US & Global Projects on Blockbuster and Niche Medical Products.
Our Team is a Preferred Research and Strategy Partner of Top Pharmaceutical and Device Manufacturers.
NOVEL has a Large Network of Internal and External Stakeholders, including KOLs, Payers and Patient Advocacy Groups.
NOVEL's team has received prestigious awards from top federal agencies such as FDA (all merit based honors , including awards given by the FDA's Chief Commissioner and FDA's Head of CDRH), AMCP (Two Platinum Medals that are given only to 5-6 presentations every year), AACR (Special Recognition Award) and ISPOR (multiple nominations for Best Research Award)
NOVEL Selected for 23 Presentations at ISPOR Baltimore
NOVEL was selected for 23 peer-reviewed presentations at ISPOR Baltimore. NOVEL was also selected for PODIUM session and two award-finalists. Watch 1 minute Replay of our Podium Presentation.
Podium & Poster Presentations at HTAi Seoul, Korea
At the Health Technology Assessment HTAi Annual Meeting in Seoul, Korea, NOVEL's team was selected for podium and poster presentations.
Strategy Overview on Breakthrough Therapy Designations
NOVEL just published a comprehensive overview on all Breakthrough Therapy Designated products, covering their clinical, HEOR, and comparative effectiveness.
NOVEL Won Two Platinum and Bronze Medal Awards at AMCP
NOVEL's team won two Platinum and Bronze Medal Awards for Presentations at AMCP Nexus Educational Conference at Boston.
Annual Strategy Perspective in Nature Biotechnology
Our annual strategy series has been cited and quoted more than two hundred times.